azomycin has been researched along with Neoplasms in 240 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 99 (41.25) | 18.7374 |
| 1990's | 33 (13.75) | 18.2507 |
| 2000's | 43 (17.92) | 29.6817 |
| 2010's | 57 (23.75) | 24.3611 |
| 2020's | 8 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abuteen, A; Dietz, C; Mohammad, I; Smith, MB; Zanganeh, S; Zhou, F; Zhu, Q | 1 |
| Beiki, D; Binns, D; Cullinane, C; Ehrlichmann, W; Hicks, R; Kumar, P; Machulla, HJ; Naimi, E; Reischl, G; Roselt, P; Wiebe, LI; Yang, J | 1 |
| Krohn, KA; Rajendran, JG | 1 |
| Angermeier, A; Della Manna, D; Larimer, BM; Li, Y; Reeves, KM; Song, PN; Sorace, AG; Wang, J; Yang, ES | 1 |
| Deep, G; Kim, S; Kumar, D; Rios-Colon, L; Su, Y | 1 |
| Labiano, S; Rodriguez-Ruiz, ME; Serrano-Mendioroz, I | 1 |
| Li, Y; Liu, M; Wang, Z; Zhao, Y; Zheng, Y | 1 |
| Hay, MP; Hicks, KO; Hong, CR; Jamieson, SMF; Liew, LP; Shome, A; Wong, WW | 1 |
| Ackerley, DF; Anderson, RF; Ashoorzadeh, A; Copp, JN; Flanagan, JU; Guise, CP; Mowday, AM; Patterson, AV; Rich, MH; Smaill, JB; Williams, EM | 1 |
| Cheng, W; Hu, Y; Tian, X; Wang, S; Yang, Z | 1 |
| Chen, H; Duan, K; Guo, J; Li, R; Wan, H; Xu, Y; Yuan, Z; Zhang, J; Zheng, J | 1 |
| Bernauer, C; Chisholm, JC; Lepicard, EY; Man, YKS; Robinson, SP; Shipley, JM | 1 |
| Bai, R; Chen, C; Du, P; Gao, F; Li, J; Liu, J; Liu, S; Liu, T; Lu, X; Ma, M; Qin, F; Wang, Y; Zhou, H | 1 |
| Bayin, NS; Placantonakis, DG | 1 |
| Ding, JS; Yang, YJ | 1 |
| Chang, H; Dong, H; Lu, H; Meng, X; Zhang, K; Zhang, X; Zhang, Y | 1 |
| Chen, Z; Cui, L; Li, Y; Long, M; Lu, A; Zhu, L | 1 |
| Baker, JHE; Kozlowski, P; Minchinton, AI; Moosvi, F; Reinsberg, SA; Yung, A | 1 |
| Shimizu, Y | 1 |
| Cao, J; Hong, H; Kung, HF; Liu, Y; Qiao, J; Yao, X; Zha, Z; Zhang, A; Zhang, L; Zhang, Y; Zhao, R; Zhu, L | 1 |
| Bohlander, SK; Devaux, JBL; Hart, CP; Hickey, AJR; Hong, CR; Hunter, FW; Kakadia, PM; Ketela, TW; Khan, A; Marastoni, S; Meng, F; Print, CG; Shalev, Z; Sharma, I; Tsai, P; Wilson, WR; Wouters, BG | 1 |
| Kosaka, M; Sakai-Sawada, K; Takei, N; Tamura, Y; Yoneda, A | 1 |
| Aguirre, A; Kuhn, L; Mohammad, I; Smith, MB; Wang, T; Xu, Y; Yang, Y; Zanganeh, S; Zhu, Q | 1 |
| Ashoorzadeh, A; Ding, K; Guise, CP; Lin, WH; Mowday, AM; Patterson, AV; Smaill, JB; Wu, DH; Yuan, R | 1 |
| Lü, HX; Pang, H; Wang, WQ; Zhang, ZH; Zhou, JP | 1 |
| Hara, D; Ito, T; Kawasaki, A; Son, A; Tanabe, K | 1 |
| Baldry, C; Blower, PJ; Domarkas, J; Fleming, IN; Gilbert, FJ; Harris, AL; Lord, S; Manavaki, R; West, C; Williams, KJ | 1 |
| Dubois, L; Lambin, P; Peeters, SG; Van Elmpt, W; Yaromina, A; Zegers, CM | 1 |
| Brindell, M; Kieda, C; Mazuryk, O; Suzenet, F | 1 |
| Bukala, D; Eichner, M; Feger, M; Fuchs, K; Harant, M; Kneilling, M; Lang, F; Mahling, M; Maier, FC; Pichler, BJ; Reischl, G; Reutershan, J; Thaiss, WM | 1 |
| Aung, W; Endo, H; Fujibayashi, Y; Furukawa, T; Hasegawa, S; Inoue, M; Jin, ZH; Saga, T; Yoshii, Y; Yuan, Q; Zhang, MR | 1 |
| Chen, LW; Duan, YT; Tang, DJ; Tao, XX; Wang, PF; Xu, C; Yang, MR; Zhu, HL | 1 |
| Bahce, I; Boellaard, R; de Langen, AJ; Hoekstra, OS; Huisman, MC; Iqbal, R; Kramer, GM; Lammertsma, AA; van Velden, FH; Verwer, EE; Windhorst, AD | 1 |
| Yoshimoto, M | 1 |
| Cabrales, P; Minchinton, A; Oronsky, B; Scicinski, J | 1 |
| Hisano, H; Ikeda, Y; Nagasaki, Y; Nishikawa, Y | 1 |
| Bacchu, V; Elsaidi, HR; Kumar, P; Laurens, E; Wang, M; Wiebe, LI; Yang, J; Zorniak, B | 1 |
| Krohn, KA; Link, JM; Mason, RP | 1 |
| Busk, M; Bussink, J; Horsman, MR; Jakobsen, S; Overgaard, J; van der Kogel, A | 1 |
| Banerjee, S; Mallia, MB; Mathur, A; Sarma, HD; Subramanian, S; Venkatesh, M | 1 |
| Chen, Q; Deng, X; He, F; Huang, Y; Li, GC; Ling, CC; Liu, Y; Minami, A; Sun, X; Wen, B; Xing, L; Zanzonico, PB | 1 |
| Eskola, O; Grönroos, TJ; Komar, G; Lehtiö, K; Minn, H; Seppänen, M; Solin, O; Tuomela, J | 1 |
| Bestetti, RB; Theodoropoulos, TA | 1 |
| Abrams, DN; Kumar, P; McEwan, AJ; Postema, EJ; Riauka, TA; Richmond, DA; Wiebe, LI | 1 |
| Kizaka-Kondoh, S; Konse-Nagasawa, H | 1 |
| Bennewith, KL; Cairns, RA; Chang, DT; Denko, NC; Giaccia, AJ; Graves, EE | 1 |
| Humm, JL; Li, XF; Ling, CC; Ma, Y; O'Donoghue, JA; Russell, J; Suehiro, M; Sun, X; Zhang, M | 1 |
| Campbell, MJ; Cross, K; Eaton, D; Halbert, G; Judson, I; Leach, MO; Lee, CP; McNamara, J; Oregioni, A; Payne, GS; Raynaud, FI; Ruddle, R; Seddon, B; Tan, S; Tracy, M; Workman, P | 1 |
| Möller, A; Young, RJ | 1 |
| Bol, A; Christian, N; De Bast, M; Deheneffe, S; Grégoire, V; Labar, D; Lee, JA | 1 |
| Aerts, HJ; Brans, B; De Ruysscher, D; Dingemans, AM; Dubois, L; Hochstenbag, M; Janssen, MH; Kolb, H; Lalisang, R; Lambin, P; Ollers, M; van Dongen, GA; van Loon, J; Windhorst, B; Zhang, J | 1 |
| Busch, TM | 1 |
| Baumann, M; Beuthien-Baumann, B; Bussink, J; Eicheler, W; Krause, M; Rijken, P; Santiago, A; van der Kogel, AJ; Yaromina, A | 1 |
| Busk, M; Horsman, MR; Jakobsen, S; Munk, OL; Overgaard, J; Skals, M; Steiniche, T; Wang, T | 1 |
| Cerecetto, H; Fernández, S; Giglio, J; Rey, A | 1 |
| Chitneni, SK; Dewhirst, MW; Palmer, GM; Zalutsky, MR | 1 |
| Carreau, A; El Hafny-Rahbi, B; Grillon, C; Kieda, C; Matejuk, A | 1 |
| Bouvet, VR; Wiebe, LI; Wuest, F; Wuest, M | 1 |
| Bendell, JC; Borad, MJ; Burris, HA; Chiorean, EG; Infante, JR; Jones, SF; Kroll, S; Lacouture, ME; Langmuir, VK; Lee, H; Lewandowski, K; Molina, JR; Ramanathan, RK; Tibes, R; Weiss, GJ | 1 |
| Aki, H; Fukumura, T; Furutsuka, K; Hayashi, K; Muto, M; Nakao, R; Suzuki, K; Takei, M | 1 |
| Astner, ST; Bayer, C; Maftei, CA; Shi, K; Vaupel, P | 1 |
| Liu, K; Zhu, HL | 1 |
| Aguirre, A; Biswal, NC; Claffey, KP; Kuhn, LT; Pavlik, C; Smith, MB; Xu, Y; Zanganeh, S; Zhu, Q | 1 |
| Hammerschmidt, F; Schweifer, A | 1 |
| Anderson, RF; Banica, M; Bhupathi, D; Cai, X; Duan, JX; Evans, JW; Glazer, PM; Guise, CP; Hart, CP; Lan, L; Lorente, G; Maroz, A; Matteucci, MD; Meng, F; Mowday, AM; Patterson, AV; Stachelek, GC | 1 |
| Sharma, R | 2 |
| Kadonosono, T; Kizaka-Kondoh, S; Nagasawa, H; Okabe, Y; Okuda, K; Ueno, T; Youssif, BG | 1 |
| Hayallah, AA; Hussein, MA; Kadonosono, T; Kizaka-Kondoh, S; Nagasawa, H; Okuda, K; Salem, OI; Youssif, BG | 1 |
| Moyer, MW | 1 |
| Cerecetto, H; Fernández, S; Giglio, J; Rey, AM | 1 |
| Cheeseman, C; Khlebnikov, V; Kumar, P; Liang, H; Shustov, G; Wiebe, LI; Yang, XH; Zheng, W | 1 |
| Ali, MS; Kohanim, S; Kong, FL; Mendez, R; Rollo, A; Smith, DL; Yang, DJ | 1 |
| Hoigebazar, L; Jeong, JM | 1 |
| Cooper, ME; Gjertsen, BT; Haug, BE; Lorens, JB; McCormack, E; Micklem, DR; Pavlin, T; Silden, E; West, RM | 1 |
| Broggini-Tenzer, A; Hug, D; Orlowski, K; Pruschy, M; Rohrer Bley, C; Soltermann, A; Vuong, V; Zimmermann, M | 1 |
| Bergman, J; Eskola, O; Kulmala, J; Lehtiö, K; Minn, H; Oikonen, V; Tolvanen, T | 1 |
| Evans, SM; Koch, CJ | 1 |
| Begg, AC | 1 |
| Grimshaw, R; Halbert, G; Judson, I; Leach, MO; Payne, GS; Raynaud, F; Ruddle, R; Seddon, BM; Simmons, L; Tan, S; Turner, A; Workman, P | 1 |
| Frischer, JS; Holash, J; Huang, J; Kadenhe-Chiwishe, A; Kandel, JJ; Kim, ES; Lee, A; New, T; Pollyea, DA; Serur, A; Yamashiro, DJ; Yancopoulos, GD; Yokoi, A | 1 |
| Mechetner, E; Samoszuk, MK; Walter, J | 1 |
| Aquino-Parsons, C; Olive, PL | 1 |
| Griffiths, JR; Robinson, SP | 1 |
| Ito, M; Ogino, H; Shibamoto, Y; Sugie, C | 1 |
| Seddon, BM; Workman, P | 1 |
| Beck, R; Kumar, P; Machulla, HJ; McEwan, AJ; Picchio, M; Piert, M; Reischl, G; Schwaiger, M; Wester, HJ; Wiebe, LI; Ziegler, S | 1 |
| Burgman, P; Burnazi, E; Cai, S; Finn, RD; Humm, JL; Lewis, JS; Ling, CC; O'Donoghue, JA; Pugachev, A; Ruan, S; Smith-Jones, P; Welch, MJ; Wen, B; Zanzonico, P | 1 |
| Campa, J; Carlin, S; Humm, JL; Larson, SM; Ling, CC; Pugachev, A; Ruan, S | 1 |
| Kumar, P; McEwan, AJ; Naimi, E; Wiebe, LI | 1 |
| Begg, AC; Bussink, J; Kaanders, JH; Ljungkvist, AS; Raleigh, JA; Rijken, PF; van der Kogel, AJ | 1 |
| Aquino-Parsons, C; Olive, P; Sobhanifar, S; Stanbridge, EJ | 1 |
| Chou, SC; Ji, X; Kleiter, MM; Lee, DY; Malarkey, DE; Raleigh, JA; Thrall, DE | 1 |
| Fernández-Braña, M | 1 |
| Parker, CA; Stratford, IJ; Williams, KJ | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, M; Troost, EG; van der Kogel, AJ | 1 |
| Banerjee, S; Mallia, MB; Sarma, HD; Subramanian, S; Venkatesh, M | 1 |
| Burgman, P; Chen, Q; Diaz-Gonzalez, JA; Li, XF; Ling, CC; Russell, J; Shin, KH | 1 |
| Caetano, PK; Calvi, SA; de Carvalho, TB; Lima, CR; Machado, JM; Nagoshi, LR; Persi, E; Picka, MM; Ribeiro, DA; Salvadori, DM | 1 |
| Bol, A; Christian, N; De Bast, M; Grégoire, V; Labar, D; Lee, J; Mahy, P | 1 |
| Eykyn, TR; Gabellieri, C; Leach, MO | 1 |
| Binns, D; Cullinane, C; Dorow, DS; Hicks, RJ; Katsifis, A; Reischl, G; Roselt, P | 1 |
| Eschmann, SM; Langen, KJ | 1 |
| Brown, JM | 2 |
| Adams, GE | 4 |
| Coleman, CN; Phillips, TL; Urtasun, RC; Wasserman, TH | 1 |
| Denekamp, J; Fowler, JF; Williams, MV | 1 |
| Coleman, CN; Halsey, J; Hancock, S; Harris, JW; Hirst, VK; Urtasun, RC; Wasserman, TH | 1 |
| Phillips, TL | 2 |
| Chu, FC; Kim, JH | 1 |
| Onoyama, Y | 1 |
| Dische, S | 2 |
| Siemann, DW | 1 |
| Brown, JM; White, RA; Workman, P | 1 |
| Fulton, DS; Raleigh, J; Tanasichuk, H; Urtasun, RC | 1 |
| Bleehen, NM; Lee, FY; Roberts, JT; Walton, MI; Workman, P | 1 |
| Bleehen, NM; Roberts, JT; Walton, MI; Workman, P | 2 |
| Anderson, PJ; Bennett, MH; Dische, S; Minchinton, A; Saunders, MI; Stratford, MR; Tothill, M | 1 |
| Overgaard, J; Overgaard, M; Timothy, AR | 2 |
| Okajima, S; Okumura, Y | 1 |
| Abe, Y; Hong, SS; Kaneta, K; Matsuzawa, T | 1 |
| Allen, JG; Dische, S; Lenox-Smith, I; Malcolm, SL; Saunders, MI | 1 |
| Chapman, JD; Jette, DC; Wiebe, LI | 1 |
| Denekamp, J; Fowler, JF; Hill, SA; Minchinton, AI; Stratford, MR | 1 |
| Abe, Y; Hong, SS; Isobe, Y; Kaneta, K; Kawaguchi, T; Matsuzawa, T; Umegaki, Y; Yamakawa, M | 1 |
| Abe, M; Dodo, Y; Ono, K; Takahashi, M | 1 |
| Abe, M; Hiraoka, M; Ono, K; Takahashi, M | 1 |
| Groves, JK; Lee, A; Malcolm, SL | 1 |
| Carter, SK; Coleman, CN; Friedman, MK; Gribble, M; Halsey, J; Hirst, VK; Ignoffo, R; Jacobs, C; Leibel, S; Phillips, TL | 1 |
| Adams, GE; Ahmed, I; Clarke, ED; O'Neill, P; Parrick, J; Stratford, IJ; Wallace, RG; Wardman, P; Watts, ME | 1 |
| Nakatsugawa, S; Sugahara, T | 1 |
| Edwards, DI | 1 |
| Phillips, TL; VanRaalte, G; Wasserman, TH | 1 |
| Allen, JG; Bishop, A; Dische, S; Fermont, D; Lenox-Smith, I; Malcolm, SL; Saunders, MI | 1 |
| Gangji, D; Schwade, JG; Strong, JM | 1 |
| Gangji, D; Schwade, JG; Shoemaker, DD; Strong, JM; Upton, DK | 1 |
| Phillips, TL; Stetz, J; Wasserman, TH | 1 |
| Bennett, MH; Dische, S; Hauck, J; Minchinton, AI; Riley, PJ; Saunders, MI; Stratford, MR | 1 |
| Ash, DV; Smith, MR | 1 |
| White, RA; Workman, P | 1 |
| Adams, GE; Ahmed, I; Fielden, EM; O'Neill, P; Stratford, IJ | 1 |
| Denekamp, J; Fowler, JF; Joiner, MC; McNally, NJ | 1 |
| Workman, P | 1 |
| Cooper, JS; Waltzman, SB | 1 |
| Overgaard, J | 2 |
| Hodgkiss, RJ; Mehta, LK; Monney, H; Parrick, J | 1 |
| Cline, JM; Raleigh, JA; Rosner, GL; Thrall, DE | 2 |
| Adams, GE; Stratford, IJ | 2 |
| Cline, JM; La Dine, JK; Raleigh, JA; Thrall, DE | 1 |
| Laster, BH; Metzger, RL; Swenson, DH | 1 |
| Langmuir, VK | 1 |
| Cowan, DS; Hicks, KO; Wilson, WR | 1 |
| Chapman, JD; Mannan, RH; McEwan, AJ; Mercer, JR; Morin, C; Parliament, MB; Urtasun, RC; Wiebe, LI | 1 |
| Ballinger, JR; Cowan, DS; Melo, T; Park, L; Rauth, AM | 1 |
| Cherif, A; Harrod, VL; Inoue, T; Kim, CG; Kim, EE; Kuang, LR; Newman, RA; Nornoo, A; Podoloff, DA; Wallace, S; Yang, DJ | 1 |
| Bestetti, RB | 1 |
| Tocher, JH | 1 |
| Azuma, C; Raleigh, JA; Thrall, DE | 1 |
| Azuma, C; McEntee, MC; Raleigh, JA; Rosner, GL; Thrall, DE | 1 |
| Bellotti, G; Bocchi, EA; Fiorelli, A; Higuchi, ML; Jatene, A; Pileggi, F; Stolf, N; Uip, D; Vieira, ML | 1 |
| Durand, RE; Raleigh, JA | 1 |
| Hodgkiss, RJ | 1 |
| Aboagye, EO; Kelson, AB; Tracy, M; Workman, P | 1 |
| Lehnert, S | 1 |
| Ballinger, JR | 1 |
| Aquino-Parsons, C; Banáth, JP; Olive, PL | 1 |
| Denny, WA | 1 |
| Bonn, D | 1 |
| Adams, GE; Dische, S; Fowler, JF; Thomlinson, RH | 1 |
| Karim, AB | 1 |
| Kärcher, KH; Kogelnik, HD; Seitz, W; Szepesi, T | 1 |
| Chapman, JD; Urtasun, RC | 1 |
| Fowler, JF | 1 |
| Anderson, P; Dische, S; Flockhart, IR; Saunders, ME | 1 |
| Band, RP; Chapman, JD; Feldstein, ML; Marynowski, B; Rabin, HR; Shnitka, T; Starreveld, E; Urtasun, RC; Wilson, AF | 1 |
| Dische, S; Flockhart, IR; Saunders, MI | 1 |
| Gomer, CJ; Johnson, RJ; Lawrence, GA; Levin, VA; Marques, RA; Phillips, TL; Sadee, W; VanRaalte, G; Wasserman, TH | 1 |
| Anderson, P; Dische, S; Flockhart, IR; Lee, ME; Saunders, MI | 1 |
| Kogelnik, HD; Mamoli, B; Müller, M; Rathkolb, O; Wessely, P | 1 |
| Bahnemann, D; Basaga, H; Dunlop, JR; Searle, AJ; Willson, RL | 1 |
| Flockhart, IR; Malcolm, SL; Marten, TR; Parkins, CS; Ruane, RJ; Troup, D | 1 |
| Gomer, CJ; Lawrence, GA; Levine, ML; Penta, JS; Phillips, TL; Rubin, DJ; Sadee, W; Wasserman, TH | 1 |
| Dische, S; Saunders, MI | 1 |
| Bleehen, NM; Owen, LN; White, RA; Workman, P | 1 |
| Bataini, JP; Bernier, J; Brugère, J; Brunin, F; de Narbonne, J; Jaulerry, C | 1 |
| Munzenrider, JE | 1 |
| Ash, DV; Bugden, RD; Smith, MR | 1 |
| Hellmann, K | 1 |
| Denekamp, J; Flockhart, IR; McNally, NJ; Sheldon, PW | 1 |
| Coulter, JR; Turner, JV | 1 |
| Bleehen, NM; Plowman, PN; Wiltshire, CR; Workman, P | 1 |
| Band, P; Chapman, JD; Fryer, CG; Rabin, HR; Urtasun, RC; Wilson, AF | 1 |
| Hofer, KG; Hofer, MG; Ieracitano, J; McLaughlin, WH | 1 |
| Adams, GE; Dische, S; Flockhart, IR; Lee, ME; Saunders, MI | 1 |
| Daneau, D; Husson, M; Klastersky, J; Weerts-Ruhl, D | 1 |
| Adams, GE; Denekamp, J; Fowler, JF | 1 |
| Dische, S; Gray Errington, L; Thomlinson, RH | 1 |
| Stratford, MR | 1 |
| Chapman, JD; Golberg, L; Mannan, RH; McEwan, AJ; Mercer, JR; Parliament, MB; Urtasun, RC; Wiebe, LI | 1 |
| Cline, JM; LaDine, JK; Raleigh, JA; Rathman, M; Thrall, DE; Zeman, EM | 1 |
| Stratford, IJ | 1 |
| Alexander, E; Buswell, L; Coleman, CN; Harris, JR; Howes, AE; Kramer, RA; Loeffler, JS; Noll, L; Riese, N; Wen, P | 1 |
| Frei, E; Teicher, BA | 1 |
| Cline, JM; Franko, AJ; Page, RL; Raleigh, JA; Thrall, DE | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Bleehen, NM; Maughan, TS; Newman, HF; Stenning, S; Ward, R; Workman, P | 1 |
| Adams, GE; Bremner, JC; Edwards, HS; Fielden, EM; Stratford, IJ | 1 |
| Anders, MW | 1 |
| Bleehen, NM; Maughan, TS; Newman, HF; Ward, R; Workman, P | 1 |
| Coleman, CN; Halsey, J; Hancock, S; Noll, L; Phillips, TL; Urtasun, RC; Wasserman, TH | 1 |
| Coleman, CN; Harris, JR; Howes, AE; Kramer, RA; Noll, L; Zakar, J | 1 |
| Bleehen, NM; Maughan, TS; Newman, HF; Workman, P | 1 |
| Best, MW; Franko, AJ; Koch, CJ; Miller, GG; Raleigh, JA | 1 |
| Coleman, CN | 2 |
| Evans, WK; Stewart, DJ | 1 |
| Bennett, MH; Dische, S; Orchard, R; Stratford, MR; Wardman, P | 1 |
| Bleehen, NM; Newman, HF; Workman, P | 1 |
| Bennett, MH; Des Rochers, C; Dische, S; Dunphy, EP; Minchinton, AI; Orchard, RA; Saunders, MI; Stratford, MR | 1 |
| Wasserman, TH | 1 |
| Bleehen, NM; Newman, HF; Ward, R; Workman, P | 1 |
| Mulcahy, RT | 1 |
| DeGraff, W; Gamson, J; McPherson, S; Mitchell, JB; Russo, A; Zabell, A | 1 |
| Hall, EJ | 1 |
| Cossu, F; Facchini, A; Mazza, S; Rombi, GP | 1 |
| Roe, FJ | 1 |
| Gonzalez, DG; Maes, RA; Meering, PG; van Peperzeel, HA | 1 |
52 review(s) available for azomycin and Neoplasms
| Article | Year |
|---|---|
Imaging hypoxia and angiogenesis in tumors.
Topics: Cell Hypoxia; Humans; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Radionuclide Imaging | 2005 |
Hypoxia and its therapeutic possibilities in paediatric cancers.
Topics: Antineoplastic Agents; Biomarkers; Carbonic Anhydrase IX; Cell Hypoxia; Child; Combined Modality Therapy; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Magnetic Resonance Imaging; Neoplasms; Nitroimidazoles; Oxygen Consumption; Prodrugs; Tumor Hypoxia; Vascular Endothelial Growth Factor A | 2021 |
[Progress in study of nitroimidazole as hypoxia imaging agents in tumor].
Topics: Animals; Humans; Hypoxia; Neoplasms; Nitroimidazoles; Radionuclide Imaging | 2016 |
[Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
Topics: Animals; Glutathione; Glutathione Transferase; Humans; Hypoxia; Mass Spectrometry; Mice; Misonidazole; Molecular Imaging; Molecular Probes; Multidrug Resistance-Associated Proteins; Neoplasms; Nitroimidazoles; Positron-Emission Tomography | 2018 |
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Topics: Anthraquinones; Antineoplastic Agents; Aziridines; Cell Hypoxia; Humans; Indolequinones; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Nitrogen Mustard Compounds; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Tirapazamine; Triazines | 2014 |
[An overview of glycoconjugates for cancer targeting therapy and diagnosis].
Topics: Animals; Antineoplastic Agents; Drug Carriers; Energy Metabolism; Glucose; Glycoconjugates; Glycolysis; Glycosides; Humans; Ifosfamide; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 2013 |
Imaging tumour hypoxia with positron emission tomography.
Topics: Cell Hypoxia; Humans; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2015 |
Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.
Topics: Animals; Cell Hypoxia; Evidence-Based Medicine; Humans; Molecular Imaging; Neoplasms; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
[Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy].
Topics: Animals; Boron Compounds; Boron Neutron Capture Therapy; Coordination Complexes; Fluorine Radioisotopes; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Organometallic Compounds; Phenylalanine; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones | 2015 |
Molecular imaging of hypoxia.
Topics: Animals; Cell Hypoxia; Coordination Complexes; Electron Spin Resonance Spectroscopy; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Organometallic Compounds; Oximetry; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones | 2008 |
Imaging of tumor hypoxia to predict treatment sensitivity.
Topics: Animals; Cell Hypoxia; Drug Resistance, Neoplasm; Etanidazole; Humans; Hydrocarbons, Fluorinated; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease.
Topics: Allopurinol; Chagas Disease; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Neoplasms; Nitroimidazoles; Perioperative Care; Postoperative Complications; Recurrence; Trypanocidal Agents | 2009 |
Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.
Topics: Animals; Cell Hypoxia; Diagnostic Imaging; Humans; Hypoxia-Inducible Factor 1; Neoplasms; Nitroimidazoles; Oxygen | 2009 |
Molecular imaging of hypoxia.
Topics: Humans; Hypoxia; Misonidazole; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2011 |
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia.
Topics: Animals; Biomarkers; Cell Hypoxia; Erythrocytes; Humans; Hypoxia; Magnetic Resonance Spectroscopy; Mammals; Molecular Imaging; Neoplasms; Nitroimidazoles; Oxygen; Partial Pressure; Polarography; Positron-Emission Tomography; Small Molecule Libraries | 2011 |
Nitroimidazoles as anti-tumor agents.
Topics: Animals; Antineoplastic Agents; Biotransformation; Humans; Hypoxia; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Oxygen; Prodrugs; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2011 |
Nitroimidazole radiopharmaceuticals in bioimaging: part I: synthesis and imaging applications.
Topics: Animals; Cell Hypoxia; Clinical Trials as Topic; Humans; Isotope Labeling; Magnetic Resonance Imaging; Myocardial Ischemia; Neoplasms; Nitroimidazoles; Radionuclide Imaging; Radiopharmaceuticals | 2011 |
Nitroimidazole radiopharmaceuticals in hypoxia: part II cytotoxicity and radiosensitization applications.
Topics: Animals; Apoptosis; Cell Hypoxia; Combined Modality Therapy; DNA; Humans; Neoplasms; Nitroimidazoles; Phagocytosis; Radiation-Sensitizing Agents; Radiopharmaceuticals | 2011 |
Hypoxia imaging agents labeled with positron emitters.
Topics: Animals; Cell Hypoxia; Copper Radioisotopes; Fluorine Radioisotopes; Humans; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Prognostic significance of tumor oxygenation in humans.
Topics: Animals; Biomarkers; Case Management; Cell Hypoxia; Energy Metabolism; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Nitroimidazoles; Oximetry; Oxygen; Oxygen Consumption; Partial Pressure; Prognosis; Radiopharmaceuticals; Rodentia; Tomography, Emission-Computed | 2003 |
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
Topics: Adult; Aged; Biomarkers, Tumor; Chromatography, High Pressure Liquid; Female; Fluorine Radioisotopes; Half-Life; Humans; Hypoxia; Infusions, Intravenous; Magnetic Resonance Spectroscopy; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Nitroimidazoles | 2003 |
Measurement of tumor hypoxia using single-cell methods.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Monosaccharide Transport Proteins; Neoplasms; Nitroimidazoles; Oxygen Consumption; Transcription Factors | 2004 |
Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia.
Topics: Fluorine; Fluorocarbons; Humans; Hypoxia; Magnetic Resonance Spectroscopy; Neoplasms; Nitroimidazoles; Oximetry | 2004 |
The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Topics: Asian People; Cell Hypoxia; Clinical Trials as Topic; Humans; Imidazoles; Neoplasms; Nitroimidazoles; Prodrugs; Radiation; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 2004 |
The role of functional and molecular imaging in cancer drug discovery and development.
Topics: Antineoplastic Agents; Benzoquinones; Diagnostic Imaging; HSP90 Heat-Shock Proteins; Humans; Hypoxia; Lactams, Macrocyclic; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Rifabutin; Technology, Pharmaceutical; Ultrasonography | 2003 |
Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia?
Topics: Antigens, Neoplasm; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Nitroimidazoles; Oxygen | 2005 |
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Topics: Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Etanidazole; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1984 |
Sensitizers and protectors in clinical oncology.
Topics: Alkylating Agents; Amifostine; Animals; Drug Synergism; Humans; Mice; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Organothiophosphorus Compounds; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1981 |
Chemical radiation sensitizers and protectors: recent developments.
Topics: Amifostine; Cysteamine; Cysteine; DNA, Neoplasm; Humans; Neoplasms; Nitroimidazoles; Nucleic Acid Conformation; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Sulfhydryl Compounds | 1981 |
Modification of chemotherapy by nitroimidazoles.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; DNA Repair; Drug Synergism; Glutathione; Lomustine; Melphalan; Mice; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Time Factors | 1984 |
[Cancer and radiotherapy. (4). Hypoxic cell sensitizers and hyperthermia combined with radiation in cancer treatment].
Topics: Acetophenones; Animals; Hot Temperature; Humans; Mice; Misonidazole; Neoplasms; Nitrofurans; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1982 |
Radiation sensitization studies in Japan.
Topics: Animals; Cell Survival; Drug Evaluation; Half-Life; Humans; Japan; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1981 |
Mechanisms of cytotoxicity of nitroimidazole drugs.
Topics: Animals; Bacteria; Cell Survival; DNA; Drug Interactions; Drug Resistance; Humans; Neoplasms; Nitroimidazoles; Photosynthesis; Radiation-Sensitizing Agents; Structure-Activity Relationship; Sulfhydryl Compounds | 1981 |
Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
Topics: Antineoplastic Agents; Cell Hypoxia; Humans; Neoplasms; Nitroimidazoles; Oxygen; Randomized Controlled Trials as Topic | 1994 |
The use of radioimmunotherapy in combination with bioreductive agents.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cytotoxins; Humans; Immunoconjugates; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radioimmunotherapy; Triazines | 1996 |
Reductive activation of nitroheterocyclic compounds.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria, Anaerobic; Bacterial Infections; Biotransformation; Humans; Mutagens; Neoplasms; Nitrofurans; Nitroimidazoles; Oxidation-Reduction | 1997 |
Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
Topics: Animals; Biomarkers; Cell Division; Cell Hypoxia; Flow Cytometry; Humans; Neoplasms; Nitroimidazoles; Oxidation-Reduction | 1998 |
Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia
Topics: Animals; Cell Hypoxia; Humans; Magnetic Resonance Spectroscopy; Molecular Probes; Neoplasms; Nitroimidazoles; Tomography, Emission-Computed | 1998 |
Imaging hypoxia in tumors.
Topics: Animals; Cell Hypoxia; Copper Radioisotopes; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Neoplasms; Nitroimidazoles; Radionuclide Imaging; Radiopharmaceuticals; Technetium; Technetium Compounds | 2001 |
The role of hypoxia-activated prodrugs in cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Humans; Neoplasms; Nitroimidazoles; Oxides; Prodrugs; Quinones | 2000 |
Chemical modification of radiation effects.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Survival; Cysteamine; DNA; Drug Evaluation; Drug Interactions; Humans; Hypoxia; Metronidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Radiation Effects; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1977 |
Recent advances in radiotherapy.
Topics: Breast Neoplasms; Bromodeoxyuridine; Carcinoid Tumor; Elementary Particles; Fast Neutrons; Hot Temperature; Humans; Male; Melanoma; Metronidazole; Neoplasms; Nitroimidazoles; Pancreatic Neoplasms; Prostatic Neoplasms; Protons; Radiation Protection; Radiation Tolerance; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectal Neoplasms; Salivary Gland Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1977 |
Pharmacokinetics and subcellular localization of radiosensitizers.
Topics: Etanidazole; Humans; Hydrogen-Ion Concentration; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1992 |
Bioreductive drugs in cancer therapy.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Hypoxia; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1992 |
Modulation of antitumor alkylating agents (AA).
Topics: Alkylating Agents; Antineoplastic Agents; Cell Hypoxia; Cisplatin; DNA Damage; DNA Repair; Drug Combinations; Drug Interactions; Drug Resistance; Fluorocarbons; Glutathione; Glutathione Transferase; Humans; Hydroxyethyl Starch Derivatives; Indazoles; Metallothionein; Neoplasm Proteins; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Topoisomerase II Inhibitors; Xanthines | 1991 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Glutathione-dependent bioactivation of xenobiotics: implications for mutagenicity and carcinogenicity.
Topics: Animals; Antineoplastic Agents; Cysteine; DNA; DNA Damage; Glutathione; Mice; Mutagenesis; Neoplasms; Nitroimidazoles; Rats; Xenobiotics | 1990 |
Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Combined Modality Therapy; Glutathione; Humans; Idoxuridine; Interleukin-1; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1989 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione; Humans; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy | 1985 |
Hypoxic cell radiosensitizers: expectations and progress in drug development.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Etanidazole; Humans; Metronidazole; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1985 |
Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Etanidazole; Humans; Metronidazole; Misonidazole; Neoplasms; Nimorazole; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1985 |
30 trial(s) available for azomycin and Neoplasms
| Article | Year |
|---|---|
Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Female; Fluorine Radioisotopes; Glioma; Head and Neck Neoplasms; Humans; Hypoxia; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2009 |
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Cell Hypoxia; Female; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms; Nitroimidazoles; Oxygen; Partial Pressure; Young Adult | 2009 |
PET imaging of hypoxia using [18F]HX4: a phase I trial.
Topics: Aged; Cell Hypoxia; Dose-Response Relationship, Drug; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Time Factors; Triazoles | 2010 |
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cell Hypoxia; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs | 2011 |
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
Topics: Adult; Aged; Biomarkers, Tumor; Chromatography, High Pressure Liquid; Female; Fluorine Radioisotopes; Half-Life; Humans; Hypoxia; Infusions, Intravenous; Magnetic Resonance Spectroscopy; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Nitroimidazoles | 2003 |
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Topics: Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Etanidazole; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1984 |
Dose-response relationships for human tumors: implications for clinical trials of dose modifying agents.
Topics: Animals; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Etanidazole; Humans; Mice; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
[Clinical trials of hypoxic cell sensitizer misonidazole].
Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Random Allocation; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1983 |
Clinical trials with hypoxic cell sensitizers-the European experience.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Methods; Misonidazole; Neoplasms; Nitroimidazoles; Urinary Bladder Neoplasms | 1983 |
Misonidazole with dexamethasone rescue: an escalating dose toxicity study.
Topics: Adolescent; Adult; Aged; Dexamethasone; Dose-Response Relationship, Drug; Humans; Middle Aged; Misonidazole; Neoplasms; Nervous System Diseases; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Topics: Drug Evaluation; Humans; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors | 1984 |
MRC randomized studied of misonidazole in combination with radiotherapy.
Topics: Clinical Trials as Topic; Humans; Misonidazole; Neoplasms; Nitroimidazoles | 1982 |
Hypoxic cell sensitisers in radiotherapy.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Hypoxia; In Vitro Techniques; Mice; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen Consumption; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1976 |
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
Topics: Administration, Oral; Drug Administration Schedule; Drug Evaluation; Humans; Misonidazole; Nausea; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Sensation; Vomiting | 1979 |
Misonidazole-a drug for trial in radiotherapy and oncology.
Topics: Anorexia; Clinical Trials as Topic; Drug Eruptions; Female; Humans; Male; Misonidazole; Nausea; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Seizures | 1979 |
[Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
Topics: Bone Neoplasms; Clinical Trials as Topic; Glioma; Humans; Kinetics; Misonidazole; Neoplasms; Nitroimidazoles; Otorhinolaryngologic Diseases; Sarcoma | 1978 |
Anaerobic wound infections in cancer patients: comparative trial of clindamycin, tinidazole, and doxycycline.
Topics: Anaerobiosis; Bacterial Infections; Clindamycin; Double-Blind Method; Doxycycline; Drug Resistance, Microbial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Neoplasms; Nitroimidazoles; Tinidazole | 1977 |
Proceedings: The response of tumours to x rays and RO-07-0582.
Topics: Female; Humans; Methods; Neoplasms; Nitroimidazoles; Radiation Dosage; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 1976 |
Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Topics: Brachytherapy; Combined Modality Therapy; Drug Evaluation; Etanidazole; Female; Humans; Infusions, Intravenous; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors | 1992 |
The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Etanidazole; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Nitroimidazoles; Radiation-Sensitizing Agents | 1991 |
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Topics: Aged; Clinical Trials as Topic; Etanidazole; Humans; Male; Middle Aged; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1990 |
Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Topics: Adult; Canada; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; United States | 1990 |
Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Topics: Brachytherapy; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intravenous; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1989 |
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Drug Combinations; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents | 1989 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
Hypoxic cell radiosensitizers: illusion or elusion?
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1988 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione; Humans; Misonidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy | 1985 |
Update: the potential for chemosensitization of alkylating agents by nitroimidazoles.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cell Hypoxia; Clinical Trials as Topic; DNA Damage; Drug Synergism; Glutathione; Humans; Neoplasms; Nitroimidazoles; Tumor Cells, Cultured | 1988 |
Hypoxic cell radiosensitizers: expectations and progress in drug development.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Etanidazole; Humans; Metronidazole; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1985 |
Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Etanidazole; Humans; Metronidazole; Misonidazole; Neoplasms; Nimorazole; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1985 |
164 other study(ies) available for azomycin and Neoplasms
| Article | Year |
|---|---|
Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Fluorescent Dyes; Hypoxia; Indocyanine Green; Mice, Inbred BALB C; Neoplasms; Nitroimidazoles; Optical Imaging | 2015 |
β -[
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorine Radioisotopes; Male; Mice; Mice, Nude; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiochemistry; Radiopharmaceuticals; Tissue Distribution; Tumor Hypoxia | 2017 |
Topics: Cell Hypoxia; CTLA-4 Antigen; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2022 |
Immunofluorescence-Based Method to Assess Cancer Biomarker in the Hypoxic Region of the Tumor.
Topics: Biomarkers, Tumor; Cell Hypoxia; Fluorescent Antibody Technique; Humans; Hypoxia; Neoplasms; Nitroimidazoles; Tumor Microenvironment | 2022 |
Assessment of hypoxia by pimonidazole staining following radiotherapy.
Topics: Biomarkers; Cell Hypoxia; Humans; Hypoxia; Neoplasms; Nitroimidazoles; Oxygen; Staining and Labeling; Tumor Microenvironment | 2022 |
Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
Topics: Animals; Antioxidants; Cell Line, Tumor; Coenzymes; Glutathione; Humans; Hypoxia; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Sorafenib | 2023 |
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.
Topics: Cell Hypoxia; Humans; Hypoxia; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 2023 |
Engineering
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Hypoxia; Drug Monitoring; Enzyme Activation; Escherichia coli; Escherichia coli Proteins; Etanidazole; Genetic Therapy; HCT116 Cells; Humans; Hydrocarbons, Fluorinated; Imidazoles; Molecular Imaging; Neoplasms; Nitroimidazoles; Nitroreductases; Positron-Emission Tomography; Prodrugs; Protein Engineering | 2019 |
Design, synthesis, and biological study of 4-[(2-nitroimidazole-1
Topics: A549 Cells; Aniline Compounds; Antineoplastic Agents; Cell Hypoxia; ErbB Receptors; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Nitroimidazoles; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy.
Topics: Animals; Boranes; Boron Compounds; Boron Neutron Capture Therapy; Cell Hypoxia; Cell Line, Tumor; Humans; Mice; Nanoparticles; Neoplasms; Nitroimidazoles; Phenylalanine; Tissue Distribution; Xenograft Model Antitumor Assays | 2020 |
Hypoxia and pH co-triggered oxidative stress amplifier for tumor therapy.
Topics: Acrolein; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Glutathione; Humans; Hydrogen-Ion Concentration; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidative Stress; Reactive Oxygen Species; Tumor Hypoxia; Tumor Microenvironment | 2021 |
Evaluation of Vascularity, Blood Perfusion, and Oxygen Tension in Tumor Xenografts with Fluorescent Microscopy.
Topics: Animals; Disease Models, Animal; Fluorescent Antibody Technique; Heterografts; Humans; Hypoxia; Mice; Microscopy, Fluorescence; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Oxygen | 2018 |
Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy.
Topics: Animals; Antineoplastic Agents; Chlorophyllides; Delayed-Action Preparations; Humans; Light; Liposomes; MCF-7 Cells; Mice; Neoplasms; Nitroimidazoles; Optical Imaging; Photosensitizing Agents; Polyethylene Glycols; Porphyrins; Theranostic Nanomedicine; Tirapazamine; Tumor Hypoxia | 2018 |
Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts.
Topics: Animals; Cell Hypoxia; Delayed-Action Preparations; Heterografts; Humans; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Xenograft Model Antitumor Assays | 2019 |
Fast and sensitive dynamic oxygen-enhanced MRI with a cycling gas challenge and independent component analysis.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Female; HCT116 Cells; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Oxygen; Platelet Endothelial Cell Adhesion Molecule-1; Tumor Microenvironment | 2019 |
In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; Esters; Female; Fluorine Radioisotopes; Hydrolysis; Hypoxia; Male; Mice; Mice, Inbred BALB C; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radioactive Tracers; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2019 |
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; CRISPR-Cas Systems; Electron Transport; Gene Expression Regulation; Gene Regulatory Networks; HCT116 Cells; Humans; Mitochondria; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; RNA, Small Interfering; Sequence Analysis, RNA | 2019 |
ERO1α is a novel endogenous marker of hypoxia in human cancer cell lines.
Topics: Animals; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Cell Hypoxia; Cell Line, Tumor; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Membrane Glycoproteins; Mice; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Oxidoreductases | 2019 |
Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates.
Topics: Animals; Cell Line, Tumor; Coloring Agents; Equipment Design; Ethanolamine; Female; Hypoxia; Immunohistochemistry; Indocyanine Green; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Spectrometry, Fluorescence; Time Factors | 2013 |
Phosphorescent ruthenium complexes with a nitroimidazole unit that image oxygen fluctuation in tumor tissue.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Coordination Complexes; Energy Transfer; Female; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Neoplasms; Nitroimidazoles; Optical Imaging; Oxygen; Ruthenium; Transplantation, Heterologous | 2015 |
The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.
Topics: Animals; Apoptosis; Cell Adhesion; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cisplatin; Coordination Complexes; Endocytosis; Endothelial Cells; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Mice; Microscopy, Fluorescence; Neoplasms; Neovascularization, Physiologic; Nitroimidazoles; Oxidative Stress; Pyridines; RNA, Messenger; Ruthenium; Subcellular Fractions; Wound Healing | 2015 |
A Comparative pO2 Probe and [18F]-Fluoro-Azomycinarabino-Furanoside ([18F]FAZA) PET Study Reveals Anesthesia-Induced Impairment of Oxygenation and Perfusion in Tumor and Muscle.
Topics: Anesthesia; Animals; Blood Pressure; Cell Line, Tumor; Female; Isoflurane; Ketamine; Mice, Inbred BALB C; Molecular Probes; Muscles; Neoplasms; Nitroimidazoles; Oxygen; Partial Pressure; Perfusion; Positron-Emission Tomography; Respiration; Systole; Xylazine | 2015 |
A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Tracking; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiography; Thiosemicarbazones; Xenograft Model Antitumor Assays | 2015 |
Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Nitroimidazoles; Protein Kinase Inhibitors; Pyrazoles; Receptor, ErbB-2 | 2016 |
Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Female; Humans; Hypoxia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Nitroimidazoles; Oxygen Radioisotopes; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow; Water | 2016 |
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Topics: Actins; Animals; Antineoplastic Agents; Azetidines; Cell Hypoxia; Cell Line, Tumor; Epigenesis, Genetic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Neoplasm Transplantation; Neoplasms; Nitro Compounds; Nitroimidazoles; Tumor Microenvironment | 2016 |
Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Nitroimidazoles; Permeability; Prodrugs; Tumor Hypoxia | 2016 |
Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors.
Topics: Animals; Cell Line, Tumor; Glucose; Glucose Transporter Type 1; Glucosides; Heterografts; Humans; Iodine Radioisotopes; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tissue Distribution; Tumor Burden; Tumor Hypoxia | 2016 |
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage.
Topics: Animals; Binding, Competitive; Biological Transport; Cell Count; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Mice; Neoplasms; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Time Factors | 2008 |
On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Hypoxia; Mice; Molecular Structure; Neoplasms; Nitroimidazoles; Organotechnetium Compounds | 2008 |
Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
Topics: Animals; Antigens, Neoplasm; Arabinofuranosyluracil; Autoradiography; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Etanidazole; Female; Gene Expression; Green Fluorescent Proteins; Herpesvirus 1, Human; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Immunohistochemistry; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Thymidine Kinase; Tissue Distribution; Transplantation, Heterologous | 2008 |
Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Humans; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Neoplasms; Nitrogen Mustard Compounds; Nitroimidazoles; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.
Topics: Animals; Antigens, Neoplasm; Autoradiography; Biological Transport; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Cell Line, Tumor; Female; Galactosides; Humans; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Radioactive Tracers; Radiographic Image Enhancement | 2010 |
Immunohistochemical detection of tumour hypoxia.
Topics: Animals; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles | 2010 |
Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.
Topics: Animals; Carbon Radioisotopes; Disease Models, Animal; Fiducial Markers; Fluorodeoxyglucose F18; Hypoxia; Male; Mice; Neoplasms; Nitroimidazoles; Radionuclide Imaging | 2010 |
Hypoxia and perfusion labeling during photodynamic therapy.
Topics: Animals; Biomarkers; Blood Circulation; Blood Vessels; Cell Hypoxia; Dihematoporphyrin Ether; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Photochemotherapy; Platelet Endothelial Cell Adhesion Molecule-1; Tissue Fixation | 2010 |
Effect of cetuximab and fractionated irradiation on tumour micro-environment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2010 |
Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.
Topics: Animals; Carcinoma, Squamous Cell; Female; Gingival Neoplasms; Humans; Hypoxia; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2010 |
Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole (99m)Tc-complexes as potential agents for targeting hypoxia.
Topics: Animals; Carbamates; Cell Hypoxia; Metronidazole; Mice; Neoplasms; Nitroimidazoles; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals | 2011 |
Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-α-D-arabinofuranosyl)-2-nitroimidazole using microfluidic technology.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Female; Mice; Mice, Inbred BALB C; Microfluidic Analytical Techniques; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiochemistry; Ribose | 2011 |
High-yield automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for hypoxia-specific tumor imaging.
Topics: Automation; Cell Hypoxia; Fluorine Radioisotopes; Humans; Neoplasms; Nitroimidazoles | 2011 |
Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques.
Topics: Benzimidazoles; Cell Hypoxia; Cell Line, Tumor; Diffusion; Humans; Microcirculation; Microscopy, Fluorescence; Microvessels; Neoplasms; Nitroimidazoles; Perfusion Imaging; Prognosis; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2011 |
Imaging tumor hypoxia by near-infrared fluorescence tomography.
Topics: Animals; Cell Hypoxia; Female; Immunohistochemistry; Indocyanine Green; Mice; Mice, Inbred BALB C; Molecular Imaging; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Spectrometry, Fluorescence; Spectroscopy, Near-Infrared; Tomography | 2011 |
Preparation of nucleosides derived from 2-nitroimidazole and D-arabinose, D-ribose, and D-galactose by the Vorbrüggen method and their conversion to potential precursors for tracers to image hypoxia.
Topics: Acetonitriles; Animals; Arabinose; Galactose; Humans; Hypoxia; Isomerism; Magnetic Resonance Spectroscopy; Molecular Imaging; Neoplasms; Nitroimidazoles; Nucleosides; Radioactive Tracers; Ribose; Silanes | 2011 |
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Cell Survival; CHO Cells; Comet Assay; Cricetinae; Cricetulus; DNA Damage; Dose-Response Relationship, Drug; HCT116 Cells; Histones; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Oxygen; Phosphoramide Mustards; Phosphorylation; Prodrugs; Spheroids, Cellular; Tumor Stem Cell Assay | 2012 |
2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia.
Topics: Animals; Carbocyanines; Cell Hypoxia; Fluorescent Dyes; Mice; Mice, Nude; Neoplasms; Nitroimidazoles; Spectroscopy, Near-Infrared | 2012 |
Development of a hypoxia-selective near-infrared fluorescent probe for non-invasive tumor imaging.
Topics: Animals; Carbocyanines; Cell Hypoxia; Cell Line, Tumor; Fluorescence; Fluorescent Dyes; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Nitroimidazoles; Solubility; Spectroscopy, Near-Infrared | 2012 |
Targeting hypoxia brings breath of fresh air to cancer therapy.
Topics: Cell Hypoxia; Clinical Trials as Topic; Humans; Neoplasms; Nitroimidazoles; Phosphoramide Mustards | 2012 |
Influence of ligand denticity on the properties of novel ⁹⁹mTc(I)-carbonyl complexes. Application to the development of radiopharmaceuticals for imaging hypoxic tissue.
Topics: Animals; Cell Line, Tumor; Click Chemistry; Contrast Media; Coordination Complexes; Diagnostic Imaging; Humans; Ketones; Ligands; Metronidazole; Mice; Mice, Inbred C57BL; Neoplasms; Nitroimidazoles; Protein Binding; Proteins; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Technetium; Tissue Distribution | 2012 |
Design, synthesis, and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors.
Topics: Cell Hypoxia; Cell Line, Tumor; Drug Design; Glucose Transport Proteins, Facilitative; Glucosides; Glycosides; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Transcriptional Activation | 2012 |
Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia.
Topics: Animals; Cell Hypoxia; Female; Heterocyclic Compounds, 1-Ring; Humans; Male; Molecular Imaging; Neoplasms; Nitroimidazoles; Organotechnetium Compounds; Oxygen; Rabbits; Radioactive Tracers; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Inbred F344; Tissue Distribution; Tumor Microenvironment | 2012 |
Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer.
Topics: Animals; Anti-Infective Agents; Carbocyanines; Cell Line, Tumor; Cell Survival; Escherichia coli Proteins; Green Fluorescent Proteins; HEK293 Cells; Humans; Luciferases; Magnetic Resonance Imaging; Metronidazole; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasms; Nitroimidazoles; Nitroreductases; Reproducibility of Results; Transfection; Xenograft Model Antitumor Assays | 2013 |
Dynamics of tumor hypoxia in response to patupilone and ionizing radiation.
Topics: Animals; Biomarkers, Tumor; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cobalt; Combined Modality Therapy; Epothilones; Genes, Reporter; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Mice; Mice, Nude; Neoplasms; Nitroimidazoles; Oxygen; Partial Pressure; Protein Structure, Tertiary; Radiation, Ionizing; Xenograft Model Antitumor Assays | 2012 |
18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies.
Topics: Female; Fluorine Radioisotopes; Humans; Male; Misonidazole; Neoplasms; Nitroimidazoles; Radiation Dosage; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Is HIF-1alpha a good marker for tumor hypoxia?
Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Flow Cytometry; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Transcription Factors | 2003 |
TNP-470 promotes initial vascular sprouting in xenograft tumors.
Topics: Angiogenesis Inhibitors; Angiography; Animals; Antibiotics, Antineoplastic; Apoptosis; Capillaries; Cell Line, Tumor; Cyclohexanes; Fluorescein; Humans; Hypoxia; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Lectins; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; O-(Chloroacetylcarbamoyl)fumagillol; Radiation-Sensitizing Agents; Sesquiterpenes; Vascular Endothelial Growth Factor A; Wilms Tumor | 2004 |
Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors.
Topics: Animals; Antibodies, Monoclonal; Cell Hypoxia; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Organ Specificity | 2004 |
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Topics: Animals; Cell Hypoxia; Disease Models, Animal; Female; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Organ Specificity; Oxidation-Reduction; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2005 |
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
Topics: Animals; Autoradiography; Benzimidazoles; Cell Hypoxia; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Microscopy, Fluorescence; Misonidazole; Neoplasms; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rats, Nude; Thiosemicarbazones; Transplantation, Heterologous | 2005 |
Dependence of FDG uptake on tumor microenvironment.
Topics: Animals; Autoradiography; Benzimidazoles; Bromodeoxyuridine; Cell Hypoxia; Cell Proliferation; Coloring Agents; Fluorodeoxyglucose F18; Glucose; Male; Mice; Mice, Nude; Neoplasms; Nitroimidazoles; Prostatic Neoplasms; Radiopharmaceuticals | 2005 |
A one-pot synthesis of 1-alpha- and 1-beta-D-arabinofuranosyl-2-nitroimidazoles: synthons to the markers of tumor hypoxia.
Topics: Biomarkers, Tumor; Cell Hypoxia; Molecular Structure; Monosaccharides; Neoplasms; Nitroimidazoles | 2005 |
Hypoxic cell turnover in different solid tumor lines.
Topics: Animals; Benzimidazoles; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Coloring Agents; Half-Life; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nitroimidazoles; Time Factors | 2005 |
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.
Topics: Animals; Antigens, Neoplasm; Astrocytoma; Biomarkers, Tumor; Biopsy; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Female; Flow Cytometry; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Image Processing, Computer-Assisted; Mice; Mice, SCID; Necrosis; Neoplasms; Nitroimidazoles; Transcription Factors; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2005 |
A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker.
Topics: Administration, Oral; Animals; Area Under Curve; Cell Hypoxia; Cell Line; Cricetinae; Cricetulus; Dog Diseases; Dogs; Feasibility Studies; Hydrogen-Ion Concentration; Injections, Intravenous; Neoplasms; Nitroimidazoles | 2006 |
[Hypoxia: a therapeutic target].
Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cyclic N-Oxides; Drug Resistance, Neoplasm; Glycolysis; Humans; Hypoxia-Inducible Factor 1; Neoplasm Proteins; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Oxygen; Quinones; Radiation Tolerance; Radiation-Sensitizing Agents; Reducing Agents | 2005 |
Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging | 2006 |
Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia.
Topics: Animals; Drug Carriers; Drug Stability; Fibrosarcoma; Hypoxia; Ligands; Mice; Neoplasms; Nitroimidazoles; Organotechnetium Compounds; Tissue Distribution | 2006 |
Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole.
Topics: Animals; Antigens, Neoplasm; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Cell Line, Tumor; Humans; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Oxygen Consumption | 2007 |
DNA damage and nitric oxide synthesis in experimentally infected Balb/c mice with Trypanosoma cruzi.
Topics: Animals; Blood Cells; Chagas Disease; DNA Damage; Liver; Male; Mice; Mice, Inbred BALB C; Myocardium; Neoplasms; Nitric Oxide; Nitroimidazoles; Random Allocation; Spleen; Trypanocidal Agents; Trypanosoma cruzi | 2007 |
Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
Topics: Animals; Area Under Curve; Hypoxia; Liver; Male; Mice; Mice, Inbred C3H; Neoplasms; Nitroimidazoles; Ornidazole; Positron-Emission Tomography; Radiopharmaceuticals; Spironolactone; Time Factors; Tissue Distribution; Treatment Outcome | 2007 |
Conformational exchange in pimonidazole--a hypoxia marker.
Topics: Animals; Biomarkers; Cell Hypoxia; Humans; Magnetic Resonance Spectroscopy; Molecular Conformation; Neoplasms; Nitroimidazoles | 2007 |
Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Female; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution | 2007 |
Correlative imaging of hypoxia and angiogenesis in oncology.
Topics: Autoradiography; Cell Hypoxia; Glucosides; Humans; Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Oligopeptides; Positron-Emission Tomography | 2008 |
Clinical perspectives for the use of new hypoxic cell sensitizers.
Topics: Animals; Cyclophosphamide; Dogs; Drug Therapy, Combination; Etanidazole; Humans; Melphalan; Mice; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Solubility | 1982 |
Radiosensitizers: a conference preview.
Topics: Animals; Aziridines; Buthionine Sulfoximine; Carmustine; Combined Modality Therapy; Drug Synergism; Etanidazole; Humans; Ketones; Lomustine; Maleates; Methionine Sulfoximine; Mice; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
Topics: Drug Evaluation; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors | 1984 |
The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
Topics: Administration, Oral; Animals; Biological Availability; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Etanidazole; Female; Injections, Intravenous; Kinetics; Male; Misonidazole; Neoplasms; Nervous System; Nitroimidazoles; Radiation-Sensitizing Agents; Structure-Activity Relationship | 1980 |
Hypoxia-mediated radiation and chemo-sensitizing drugs.
Topics: Animals; Drug Synergism; Humans; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1984 |
Chemical modifiers of cancer treatment. Part 1. Banff, Canada, 27 November-1 December, 1983.
Topics: Animals; Combined Modality Therapy; Humans; In Vitro Techniques; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
A phase I study of the combination of benznidazole and CCNU in man.
Topics: Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Lomustine; Neoplasms; Nitroimidazoles; Trypanocidal Agents | 1984 |
The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.
Topics: Drug Evaluation; Female; Humans; Male; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors; Tissue Distribution | 1984 |
A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Nimorazole; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors | 1984 |
The effect of a hypoxic cell sensitizer on cancer radiotherapy: an analysis by a model.
Topics: Humans; Hypoxia; Mathematics; Misonidazole; Models, Theoretical; Neoplasms; Nitroimidazoles | 1984 |
Radiosensitizing drugs in relation to individualized treatment.
Topics: Alkylating Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Hypoxia; In Vitro Techniques; Misonidazole; Neoplasms; Nervous System; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Sulfhydryl Reagents | 1984 |
Combined treatment of radiation and local injections of misonidazole.
Topics: Combined Modality Therapy; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |
The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans.
Topics: Adult; Aged; Blood Proteins; Erythrocytes; Feces; Female; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Neoplasms; Nitroimidazoles; Oxides; Protein Binding; Radiation-Sensitizing Agents; Time Factors | 1984 |
Electron-affinic compounds for labelling hypoxic cells: the synthesis and characterization of 1-[2-(2-iodophenoxy)-ethyl]-2-nitroimidazole.
Topics: Animals; Male; Mice; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radionuclide Imaging; Tissue Distribution | 1984 |
Radiosensitization of a mouse tumour by Ro 03-8799: acute and protracted administration.
Topics: Animals; Injections, Intraperitoneal; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1983 |
[Clinical studies of combined therapy of radiation and local injection of misonidazole].
Topics: Adult; Aged; Female; Humans; Injections; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles; Radiotherapy Dosage | 1983 |
[Clinical study on radiotherapy in combination with misonidazole].
Topics: Aged; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles; Pharyngeal Neoplasms; Radiation-Sensitizing Agents | 1983 |
High-performance liquid chromatographic analysis of the new hypoxic cell radiosensitiser, Ro 03-8799, in biological samples.
Topics: Animals; Bile; Chromatography, High Pressure Liquid; Erythrocytes; Humans; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Rats; Spectrophotometry, Ultraviolet; Time Factors | 1983 |
Studies of the pharmacokinetic properties of nimorazole.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Intestinal Absorption; Male; Middle Aged; Neoplasms; Nimorazole; Nitroimidazoles; Time Factors | 1983 |
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles | 1983 |
Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Cricetinae; Cricetulus; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Structure-Activity Relationship | 1980 |
Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage.
Topics: Adult; Biological Availability; Capsules; Drug Administration Schedule; Drug Evaluation; Half-Life; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Tablets | 1982 |
The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
Topics: Adult; Aged; Female; Half-Life; Humans; Male; Necrosis; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1982 |
I.V. misonidazole (NSC 261037). Report of initial clinical experience.
Topics: Adult; Aged; Bile; Female; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles | 1981 |
Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract.
Topics: Biological Availability; Dose-Response Relationship, Drug; Half-Life; Humans; Intestinal Absorption; Kinetics; Misonidazole; Neoplasms; Nitroimidazoles | 1981 |
Clinical trials of misonidazole in the United States.
Topics: Drug Evaluation; Head and Neck Neoplasms; Humans; Misonidazole; Neoplasm Metastasis; Neoplasms; Nervous System Diseases; Nitroimidazoles | 1981 |
The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
Topics: Breast Neoplasms; Female; Humans; Misonidazole; Necrosis; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time Factors; Uterine Cervical Neoplasms | 1981 |
Causes of apparent low levels of misonidazole in human tumours.
Topics: Adipose Tissue; Animals; Brain Neoplasms; Humans; In Vitro Techniques; Liver Neoplasms; Mammary Neoplasms, Experimental; Mice; Misonidazole; Muscles; Neoplasms; Nitroimidazoles; Rats | 1980 |
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
Topics: Animals; Biological Availability; Dog Diseases; Dogs; Half-Life; Kinetics; Male; Misonidazole; Neoplasms; Nitroimidazoles | 1980 |
The development of some nitroimidazoles as hypoxic cell sensitizers.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Structure-Activity Relationship | 1980 |
Misonidazole in fractionated radiotherapy: are many small fractions best?
Topics: Animals; Cell Survival; Drug Administration Schedule; Female; Male; Misonidazole; Models, Biological; Neoplasms; Nitroimidazoles; Oxygen; Radiotherapy Dosage | 1980 |
Pharmacokinetics of hypoxic cell radiosensitizers: a review.
Topics: Administration, Oral; Animals; Cell Membrane Permeability; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Injections, Intraperitoneal; Injections, Intravenous; Kinetics; Male; Membrane Lipids; Mice; Models, Biological; Neoplasms; Nerve Tissue; Nitroimidazoles; Radiation-Sensitizing Agents; Structure-Activity Relationship; Tissue Distribution | 1980 |
Nature and incidence of misonidazole-produced ototoxicity.
Topics: Adult; Aged; Female; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles | 1981 |
Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP.
Topics: Biomarkers; Cell Hypoxia; Cells, Cultured; Magnetic Resonance Spectroscopy; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Spectrophotometry, Infrared; Theophylline | 1995 |
Distribution of the hypoxia marker CCI-103F in canine tumors.
Topics: Animals; Cell Hypoxia; Dog Diseases; Dogs; Female; Male; Neoplasms; Nitroimidazoles | 1994 |
Bioreductive drugs for cancer therapy: the search for tumor specificity.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Nitric Oxide; Nitroimidazoles; Oxidation-Reduction; Photochemotherapy; Porfiromycin; Prodrugs; Tirapazamine; Triazines | 1994 |
An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.
Topics: Animals; Biomarkers, Tumor; Calibration; Dogs; Enzyme-Linked Immunosorbent Assay; Hypoxia; Neoplasms; Nitroimidazoles; Tissue Distribution; Tritium | 1994 |
Synthesis and evaluation of a boronated nitroimidazole for boron neutron capture therapy.
Topics: Animals; Boron Compounds; Boron Neutron Capture Therapy; Cell Line; Cell Survival; Cricetinae; Dose-Response Relationship, Drug; Magnetic Resonance Spectroscopy; Molecular Structure; Neoplasms; Nitroimidazoles | 1996 |
Multicellular membranes as an in vitro model for extravascular diffusion in tumours.
Topics: Acridines; Animals; Cell Hypoxia; Cell Membrane; Cricetinae; Cricetulus; Diffusion; In Vitro Techniques; Misonidazole; Neoplasms; Nitroimidazoles; Phenanthridines | 1996 |
Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside.
Topics: Cell Hypoxia; Humans; Neoplasms; Nitroimidazoles; Tomography, Emission-Computed, Single-Photon | 1996 |
BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Hypoxia; CHO Cells; Cricetinae; Drug Resistance; Humans; Neoplasms; Nitroimidazoles; Organotechnetium Compounds; Rats | 1996 |
Development of new markers for hypoxic cells: [131I]Iodomisonidazole and [131I]Iodoerythronitroimidazole.
Topics: Animals; Breast Neoplasms; Cell Hypoxia; Female; Iodine Radioisotopes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radionuclide Imaging; Rats; Rats, Inbred F344; Tissue Distribution; Tumor Cells, Cultured | 1996 |
Should benznidazole be used in chronic Chagas' disease?
Topics: Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; Follow-Up Studies; Humans; Neoplasms; Nitroimidazoles; Trypanocidal Agents | 1997 |
Quantification of CCI-103F labeling heterogeneity in canine solid tumors.
Topics: Analysis of Variance; Animals; Biomarkers; Cell Hypoxia; Dog Diseases; Dogs; Neoplasms; Nitroimidazoles; Oxygen; Reproducibility of Results | 1997 |
Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime.
Topics: Animals; Cell Survival; DNA Adducts; DNA, Neoplasm; Dog Diseases; Dogs; Hypoxia; Neoplasms; Nitroimidazoles | 1997 |
Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning.
Topics: Animals; Biopsy; Cell Hypoxia; Dog Diseases; Dogs; Neoplasms; Nitroimidazoles | 1997 |
Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.
Topics: Adult; Carcinoma, Squamous Cell; Chagas Cardiomyopathy; Chemoprevention; Chronic Disease; Cocarcinogenesis; Cyclosporine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Immunosuppressive Agents; Incidence; Lung Diseases; Lymphoproliferative Disorders; Male; Mutagens; Neoplasms; Neurilemmoma; Nitroimidazoles; Recurrence; Sarcoma, Kaposi; Skin Neoplasms; Survival Rate; Trypanocidal Agents | 1998 |
Identification of nonproliferating but viable hypoxic tumor cells in vivo.
Topics: Animals; Bromodeoxyuridine; Cell Division; Cell Hypoxia; Cell Separation; Flow Cytometry; Humans; Mice; Mice, SCID; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Prediction of tumor response to therapy: molecular markers and the microenvironment. Apoptosis and chips: an overview of the proceedings.
Topics: Apoptosis; Biomarkers, Tumor; Biopsy; Cell Cycle; Cell Hypoxia; Cell Survival; Comet Assay; DNA Ligases; Enzyme Activation; Genes, ras; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Nitroimidazoles; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Radiation Tolerance; Radiotherapy Dosage; Tumor Cells, Cultured | 2000 |
Measuring hypoxia in solid tumours--is there a gold standard?
Topics: Biopsy, Needle; Comet Assay; Humans; Hypoxia; Microelectrodes; Neoplasms; Nitroimidazoles; Palliative Care; Predictive Value of Tests; Radiation-Sensitizing Agents; Radiotherapy; Reference Values | 2001 |
Why do hypoxic cells behave badly?
Topics: Cell Hypoxia; Humans; Immunohistochemistry; Infusions, Intravenous; Neoplasm Invasiveness; Neoplasms; Nitroimidazoles; Oxygen; Prognosis; Sensitivity and Specificity; Tumor Cells, Cultured | 2000 |
Hypoxic-cell sensitisers.
Topics: Cell Survival; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen Consumption; Radiation Tolerance | 1978 |
Hypoxic-cell sensitisers.
Topics: Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hypoxia; Metronidazole; Misonidazole; Neoplasms; Nitroimidazoles | 1978 |
[Clinical experiences with the radiation-sensitizing agent misonidazole].
Topics: Brain Neoplasms; Cardiovascular System; Central Nervous System; Digestive System; Drug Eruptions; Eye; Female; Humans; Liver; Male; Misonidazole; Neoplasms; Nitroimidazoles | 1978 |
The application in radiation therapy of substances which modify cellular radiation response.
Topics: Amifostine; Animals; Drug Evaluation; Drug Therapy, Combination; Humans; Metronidazole; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen Consumption; Radiation-Protective Agents; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1977 |
Developments in radiotherapy other than heavy particle beams.
Topics: Animals; Brain Neoplasms; Energy Transfer; Fast Neutrons; Female; Glioblastoma; Hot Temperature; Humans; Mammary Neoplasms, Experimental; Metronidazole; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; X-Rays | 1977 |
The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
Topics: Drug Administration Schedule; Half-Life; Humans; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents | 1978 |
Peripheral neuropathy related to misonidazole: incidence and pathology.
Topics: Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms; Neural Conduction; Nitroimidazoles; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; Sural Nerve | 1978 |
The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Topics: Drug Administration Schedule; Humans; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; Research Design | 1978 |
Electroneurographic investigations of misonidazole polyneuropathy.
Topics: Action Potentials; Adult; Aged; Female; Humans; Male; Middle Aged; Misonidazole; Motor Neurons; Neoplasms; Nerve Fibers; Neural Conduction; Nitroimidazoles; Peripheral Nerves; Peripheral Nervous System Diseases; Peroneal Nerve; Sural Nerve; Time Factors | 1979 |
Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy.
Topics: Cysteamine; Cysteine; Ferrous Compounds; Glutathione; Kinetics; Metronidazole; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Zinc | 1978 |
Some aspects of the metabolism of misonidazole.
Topics: Animals; Chromatography, High Pressure Liquid; Humans; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1978 |
The hypoxic cell sensitizer programme in the United States.
Topics: Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; United States | 1978 |
Clinical experience with misonidazole.
Topics: Digestive System; Humans; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Skin | 1978 |
The penetration of misonidazole into spontaneous canine tumours.
Topics: Adenocarcinoma; Anesthesia, Intravenous; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; Dog Diseases; Dogs; Female; Fibrosarcoma; Half-Life; Lymphoma, Non-Hodgkin; Male; Mammary Glands, Animal; Meningioma; Misonidazole; Neoplasms; Nitroimidazoles; Osteosarcoma; Pentobarbital | 1979 |
[New aspects of radiotherapy. I. Significance of hypoxia in irradiation of solid tumors].
Topics: Dose-Response Relationship, Radiation; Hot Temperature; Humans; Hyperbaric Oxygenation; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles | 1979 |
Distribution of misonidazole in human tumours and normal tissues.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Genital Neoplasms, Female; Humans; Male; Misonidazole; Neoplasms; Nitroimidazoles; Thyroid Diseases; Tissue Distribution; Urinary Bladder Neoplasms | 1979 |
Radiosensitizers.
Topics: Animals; Cell Survival; Humans; In Vitro Techniques; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Razoxane | 1978 |
Hypoxic cell sensitization by misonidazole in vivo and in vitro.
Topics: Cell Line; Dose-Response Relationship, Drug; Hypoxia; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1978 |
Use of metronidazole and other nitroimidazole drugs in cancer therapy.
Topics: Animals; Humans; Metronidazole; Neoplasms; Nitroimidazoles | 1978 |
Treatment of amoebiasis and giardiasis.
Topics: Child; Dysentery, Amebic; Giardiasis; Humans; Metronidazole; Neoplasms; Nitroimidazoles; Research Design; Tinidazole | 1978 |
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.
Topics: Adult; Aged; Bronchial Neoplasms; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Misonidazole; Neoplasm Metastasis; Neoplasms; Nitroimidazoles; Saliva; Skin Neoplasms | 1978 |
Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.
Topics: Chondrosarcoma; Drug Evaluation; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1977 |
Radiosensitization of hypoxic tumor cells by simultaneous administration of hyperthermia and nitroimidazoles.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Survival; Deoxyuridine; Female; Hyperthermia, Induced; Hypoxia; Leukemia L1210; Metronidazole; Mice; Mice, Inbred Strains; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Sarcoma | 1977 |
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
Topics: Adult; Aged; Humans; Middle Aged; Neoplasms; Nervous System Diseases; Nitroimidazoles; Radiation-Sensitizing Agents | 1977 |
Radiosensitizers of hypoxic cells in solid tumors.
Topics: Animals; Cells, Cultured; Cricetinae; Dose-Response Relationship, Drug; Fast Neutrons; Mammary Neoplasms, Experimental; Metronidazole; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Nitroimidazoles; Oxygen Consumption; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1976 |
Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.
Topics: Adult; Aged; Carcinoma, Small Cell; Female; Half-Life; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Nitroimidazoles; Tomography, Emission-Computed | 1992 |
Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.
Topics: Animals; Cell Hypoxia; Dogs; Enzyme-Linked Immunosorbent Assay; Liposarcoma; Neoplasms; Nitroimidazoles; Sarcoma, Synovial | 1992 |
Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.
Topics: Animals; Cell Hypoxia; Dog Diseases; Dogs; Immunohistochemistry; Neoplasms; Nitroimidazoles; Staining and Labeling | 1990 |
Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1991 |
Quantitation of hypoxia in multicellular spheroids by video image analysis.
Topics: Autoradiography; Cell Aggregation; Cell Line; Fluorescence; Humans; Image Processing, Computer-Assisted; Immunoenzyme Techniques; Neoplasms; Nitroimidazoles; Oxygen | 1989 |
The uptake of the radiosensitizing compound Ro 03-8799 (Pimonidazole) in human tumors.
Topics: Breast Neoplasms; Female; Humans; Melanoma; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Rectal Neoplasms; Uterine Cervical Neoplasms | 1989 |
A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Drug Combinations; Drug Evaluation; Etanidazole; Humans; Middle Aged; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1986 |
Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
Topics: Aged; Etanidazole; Female; Humans; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1986 |
The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Adult; Aged; Combined Modality Therapy; Drug Therapy, Combination; Etanidazole; Humans; Middle Aged; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents | 1988 |
Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells.
Topics: Animals; Cell Line; Cell Survival; Cricetinae; Cricetulus; Etanidazole; Hematoporphyrins; Neoplasms; Nitroimidazoles; Oxygen; Photochemotherapy | 1985 |
Facing fearful odds--a conference summary.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Synergism; Glutathione; Humans; Hyperbaric Oxygenation; Neoplasms; Nitroimidazoles; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1986 |
Radiosensitization by tinidazole: pharmacokinetic study.
Topics: Drug Administration Schedule; Humans; Kinetics; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Tinidazole | 1986 |
Safety of nitroimidazoles.
Topics: Abnormalities, Drug-Induced; Animals; Chromosome Aberrations; Cricetinae; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Male; Metronidazole; Mice; Mutagenicity Tests; Neoplasms; Nitroimidazoles; Pregnancy; Rats; Risk; Structure-Activity Relationship; Tinidazole | 1985 |
A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics.
Topics: Astrocytoma; Brain; Brain Diseases; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Kinetics; Neoplasms; Nitroimidazoles | 1986 |
Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
Topics: Adult; Aged; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles | 1985 |